ROCKET PHARMACEUTICALS INC (RCKT) Stock News

USA - Nasdaq - NASDAQ:RCKT - US77313F1066 - Common Stock

3.32 USD

-0.1 (-2.92%)

Last: 12/5/2025, 8:00:01 PM

3.35 USD

+0.03 (+0.9%)

After Hours: 12/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RCKT Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

19 days ago - By: Benzinga - Mentions: NICE HD HP HTHT ...

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

a month ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

4 months ago - By: Stocktwits

Why Is Rocket Pharma Stock Up 15% Pre-Market Today?

a month ago - By: Benzinga - Mentions: QURE CABA NGNE KYTX

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

a month ago - By: Bragar Eagel & Squire

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2 months ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

2 months ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Stocktwits - Mentions: IWMW ESGV

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

3 months ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm

3 months ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: AMRN AKRO ALGS

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

4 months ago - By: Stocktwits - Mentions: SRPT

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

4 months ago - By: Faruqi & Faruqi, LLP

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

4 months ago - By: The Gross Law Firm

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm

4 months ago - By: THE ROSEN LAW FIRM, P. A.

RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

4 months ago - By: Faruqi & Faruqi, LLP

Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

4 months ago - By: Berger Montague

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

4 months ago - By: The Law Offices of Frank R. Cruz

Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

4 months ago - By: Levi & Korsinsky, LLP

August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT

4 months ago - By: The Motley Fool

Rocket (RCKT) Q2 Loss Narrows 16%